Jeff Bezos Eyes $10 Billion Funding Round for AI Venture Project Prometheus 
SK Hynix Launches 192GB SOCAMM2 Memory for Nvidia’s Next-Gen AI Chips 
Greg Abel Sells Berkshire Hathaway Stocks Managed by Former Investment Manager Todd Combs 
Indian Refiners Use Yuan via ICICI Bank to Pay for Iranian Oil Under U.S. Sanctions Waiver 
Nidec Stock Rises After Accounting Probe Report Eases Delisting Concerns 
Ethiopian Airlines Expands Fleet with New Boeing 787 Dreamliner Order to Boost Global Routes 
Apple Stock Dips as Tim Cook Steps Down, John Ternus Named Next CEO 
AEVEX Raises $320 Million in IPO Amid Surging Defense Sector Demand 
Anthropic CEO Meets Trump Officials to Discuss Powerful New AI Model Mythos 
Rising Jet Fuel Costs from Iran Conflict Push Airfare Higher Across Europe 
John Ternus Signals Apple’s Future with Product-First AI Strategy 
Chinese Robotics Stocks React as Humanoid Robot Marathon Sparks Competition Concerns 
NVIDIA Acquisition Rumors Dismissed by Morgan Stanley as Strategically Flawed 
Huawei Expands Vietnam Presence Through Strategic Partnership with SHB Bank 
Amazon Expands AI Bet with Up to $25 Billion Investment in Anthropic 
Indonesia and Toyota Explore $300M Bioethanol Investment to Boost Renewable Energy Goals 
Want to cut your energy bills? Here’s how five experts are doing it 
PLANO, Texas, March 01, 2017 -- Nuvectra Corporation (NASDAQ:NVTR), a neurostimulation medical device company, announced today that Scott Drees, Chief Executive Officer, and Walter Berger, Chief Operating Officer & Chief Financial Officer, are scheduled to present at the Cowen and Company 37th Annual Health Care Conference in Boston, MA. Management will also be available for one-on-one meetings at the conference.
Event: Cowen and Company 37th Annual Health Care Conference
Date: Wednesday, March 8, 2017
Time: 8:40 am ET
A webcast of the Company’s presentation will be available by visiting the investor relations section of Nuvectra’s website at www.nuvectramed.com. A webcast replay of the presentation will be available for 90 days.
About Nuvectra Corporation
Nuvectra™ is a neurostimulation company committed to helping physicians improve the lives of people with chronic neurological conditions. The Algovita® Spinal Cord Stimulation (SCS) System is our first commercial offering and is CE marked and FDA approved for the treatment of chronic pain of the trunk and/or limbs. Our innovative technology platform also has capabilities under development to support other neurological indications such as sacral nerve stimulation (SNS), and deep brain stimulation (DBS). In addition, our NeuroNexus subsidiary designs, manufactures and markets leading-edge neural-interface technologies for the neuroscience clinical research market. Visit the Nuvectra website at www.nuvectramed.com.
Company Contacts: Nuvectra Corporation Walter Berger, Chief Operating Officer and Chief Financial Officer (214) 474-3102 [email protected] Jennifer Armstrong, Media Relations (214) 474-3110 [email protected] Investor Contacts: The Ruth Group Nick Laudico (646) 536-7030 [email protected] Zack Kubow (646) 536-7020 [email protected]
